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Abstract
Steroid 5α-reductase type I (SRD5A1) is a validated oncogene in many sex hormone-related cancers, but its role in
multiple myeloma (MM) remains unknown. Based on gene expression profiling (GEP) of sequential MM samples
during the disease course, we found that the aberrant expression of SRD5A1 was correlated with progression and poor
prognosis in MM patients. In this study, the oncogenic roles of SRD5A1 were validated in human MM cell lines (ARP1
and H929) and the xenograft MM model as well as the 5TMM mouse model. MTT and flow cytometry were used to
assess MM cell proliferation, cell cycle, and apoptosis post inducible knockdown SRD5A1 by lentivirus-mediated short-
hairpin RNA (shRNA). Transcriptomic sequencing, immunofluorescence, and western blot were used to investigate the
effects of SRD5A1 suppression on cell apoptosis and autophagy. Mechanistically, SRD5A1 downregulation
simultaneously regulated both the Bcl-2 family protein-mediated apoptosis and the autophagic process via PI3K/Akt/
mTOR signaling pathway in MM cells. Meanwhile, the autophagy inhibitor (3-methyladenine) and SRD5A1 inhibitor
(Dutasteride) were utilized to evaluate their anti-myeloma effect. Thus, our results demonstrated that SRD5A1
downregulation simultaneously regulated both the apoptosis and the autophagic process in MM cells. The dual
autophagy–apoptosis regulatory SRD5A1 may serve as a biomarker and potential target for MM progression and
prognosis.
Introduction
Multiple myeloma (MM) is the second most common
hematologic malignancy worldwide. According to statis-
tics collected in China, the incidence of MM in 2016 was
1.60 per 100,000 person-years, with 1.84 per 100,000
person-years for males and 1.30 for females, respectively1.
It is estimated that the number of new cases is over 30,000
in 2019 in the United States2. The therapies for MM have
undergone great progress over the past years, including
allogeneic hematopoietic stem cell transplantation
(ASCT) and novel chemotherapies, such as proteasome
inhibitors and immunomodulatory drugs3. However, MM
is still incurable for the majority of patients who become
refractory to treatment and ultimately relapse, thus fur-
ther development of new therapeutic agents is warranted,
such as specific inhibitors targeting activated oncogenes.
SRD5A1, a member of the steroid 5α-reductase family
(SRD5A1, SRD5A2, and SRD5A3) converting testosterone
to dihydrotestosterone (DHT), was recently reported to
be aberrantly expressed in several sex hormone-related
cancers, such as breast cancer, endometrial cancer, and
prostate cancer4–6. SRD5A1 was mainly expressed in the
skin, scalp, liver, and brain tissues, while SRD5A2 was
predominantly found in androgen target organs such as
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the prostate and genital skin, but only SRD5A1 was
upregulated in prostate cancers7,8. However, there is no
report on the oncogenic role of SRD5A1 in MM pro-
gression, considering the unequal incidence rates between
females and males of MM patients.
This study aimed to investigate the potential involve-
ment of SRD5A1 during MM pathogenesis, and the evi-
dence from in vivo and in vitro data demonstrated that
SRD5A1-mediated MM cell autophagy via PI3K/Akt/
mTOR signaling pathway and induced MM cell apoptosis
through Bcl-2 proteins family in MM. Furthermore, we
validated that Dutasteride, an SRD5A1 inhibitor, induced
myeloma cells apoptosis in human myeloma cells and
xenograft mouse models. Thus, SRD5A1 might be a
considerable therapeutic target in the development of
MM therapy.
Methods
Cell lines and cell culture
MM cell lines ARP1, OCI-MY5, and NCI-H929, which
were kind gifts from Dr. Siegfried Janz (University of Iowa,
Iowa City, IA, USA), were cultured in RPMI 1640 medium
(Biological Industries, Beit Haemek, Israel) supplemented
with 10% fetal bovine serum (FBS) (Biological Industries)
and 1% penicillin/streptomycin (P/S) solution (Sigma-
Aldrich, St. Louis, MO) under the condition of 37 °C in a
humidified atmosphere of 5% CO2. HEK-293T and
5TMM3VT, which were donated by Dr. Wen Zhou
(Xiangya School of Medicine, Central South University,
Key Laboratory of Carcinogenesis and Cancer Invasion,
Ministry of Education; Key Laboratory of Carcinogenesis,
National Health and Family Planning Commission,
Changsha, China), were cultured in DMEM medium
(Biological Industries) containing 10% FBS and 1% P/S
solution in 5% CO2 at 37 °C.
Reagent
Caspase-3 (#9662, 1:1000), Cleaved caspase-3 (#9661,
1:1000), PARP (#9542, 1:1000), Bcl-xl (#2762, 1:1000), Bcl-
2 (#2876, 1:1000), Bad (#9292, 1:1000), Bax (#2774,
1:1000), ATG-5 (#12994, 1:1000), ATG-7 (#8558, 1:1000),
LC3A/B (#12741, 1:1000), Akt (#9272, 1:1000), p-Akt
(Thr308) (#9275, 1:1000), p-mTOR (#2971, 1:1000), p-
p70S6K (Thr389) (#9234, 1:1000) and β-actin (#4970,
1:1000) antibodies were obtained from Cell Signaling
Technology (Danvers, MA, USA). SRD5A1 (#66329-1-Ig,
1:1000) and p70S6K (#14485-1-AP, 1:2000) were pur-
chased from Proteintech (Manchester, UK). The p-PI3K
(Tyr607) (#AF3241, 1:1000) and mTOR (#AF6308, 1:1000)
antibody were purchased from Affinity (Cambridge, UK).
SQSTM1/p62 (#P0067, 1:1000) antibody was obtained
from Sigma-Aldrich (St. Louis, MO, USA) and goat Anti-
rabbit IgG/Alexa Fluor 647 antibody (#bs-0295G-AF647,
1:500) was purchased from Bioss (Woburn, MA, USA).
LY2940002 (#9901) were obtained from Cell Signaling
Technology. Dutasteride (#A1659), hydroxychloroquine
(HCQ) (#B4874) and 3-methyladenine (3-MA) (#A8353)
were purchased from APExBIO (Houston, USA). Doxor-
ubicin (#D1515) was purchased from Sigma-Aldrich.
Western blotting
Briefly, whole proteins were extracted with RIPA Buffer
(#89900, Thermo Fisher, Waltham, USA) with protease
inhibitor cocktail (#20124ES03, Yeasen, Shanghai, China).
The extracts were separated by SDS-PAGE and then
transferred to 0.45-μm immobilon-P transfer membrane
(#IPVH00010, Millipore, Darmstadt, Germany). Mem-
branes were blocked with 5% skim milk for 1 h at room
temperature followed by incubation with a primary anti-
body at 4 °C overnight. Then the blots were detected with
HRP conjugated secondary antibody and visualized with
the Super ECL Detection Reagent ECL (#36208ES60,
Yeasen).
Lentiviral gene transduction




was cloned into TRIPZ vector (Thermo Fisher Scientific,
USA), which provides inducible shRNA expression in the
presence of doxycycline (Dox). Recombinant lentivirus was
produced using transient 293T cell transfection. Transfected
efficiency was verified by western blotting.
Flow cytometry
In total, 1 × 106 cells were fixed with 5mL of cold
ethanol at −20 °C overnight. After washed twice with cold
PBS, the cells were suspended with 200 μl of PBS, and
supplemented with 10 μl of RNase A stock (#10405ES03,
Yeasen) solution and incubated 60min at room tem-
perature. After incubation, cells were stained with pro-
pidium iodide (PI, # 40710ES03, Yeasen) solution (40 μg/
mL in PBS) for 15 min at room temperature and the cell
cycle was analyzed using Flowsight flow cytometer (Merck
Millipore, Darmstadt, Germany). For the cell apoptosis
experiment, the ARP1-SRD5A1-KD and H929-SRD5A1-
KD cells post 2 μg/mL treatment for 48 h at a density of
2 × 105 cells were collected and stained using Annexin-V-
Allophycocyanin (Annexin-V-APC) (#640941, BioLegend,
San Diego, USA) and PI for 15min in dark conditions,
and the apoptosis of the cells was detected using flow
cytometer.
Cell viability assay
Cells were enumerated by Trypan blue staining using a
hemocytometer (Qiujing, Shanghai, China), then were
seeded into 96-well plates at the density of 3000–4000
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cells/well. After treatments, cells were incubated with
MTT for 4 h, then the supernatant was removed, and the
formazan crystals were dissolved in 200 μL dimethyl
sulfoxide (DMSO), the optical density was measured at
570 nm.
Transcriptomic sequencing
Cells were pelleted, and RNA samples were isolated and
sent to the MicroAnaly (Shanghai, China) for construct-
ing RNA-seq library. Briefly, total RNAs were isolated,
and mRNA was enriched and then were pooled together
for cDNA synthesis and sequencing. The transcriptomic
RNA sequencing was performed on an Illumina NovaSeq
6000 platform, to create paired-end reads with a length of
150 bp (PE150). The differentially expressed genes (DEGs)
were identified using edgeR (|logFC | >1 & FDR < 0.05),
and these DEGs were undergone Gene ontology and
KEGG pathway analysis. The original raw data and
detailed processed data were submitted into Gene
Expression Omnibus (GSE155858).
Transmission electron microscopy
Cells were harvested by scraping them from the plates.
They were then washed twice with PBS and fixed with 2%
paraformaldehyde/2% glutaraldehyde in 0.2M sodium
cacodylate buffer (pH 7.4). Cell pellets were postfixed with
1% (v/v) osmic acid in sodium cacodylate buffer and were
then stained with 1% uranyl acetate. Following dehydra-
tion, pellets were embedded in Durcopan (Durcopan,
Fluka Chemie, Buchs, Switzerland). Ultrathin sections
were prepared using an ULTRACUT S ultramicrotome
and were observed with a JEM 1010 transmission electron
microscope.
Immunofluorescence
Cells were collected by cytospin on glass slides and fixed
with 4% paraformaldehyde for 15min. After washing in
10% PBS, the slides were permeabilized with 0.2% Triton
X-100 in PBS and then were blocked with 4% bovine
serum albumin (#A8020; Solarbio, Shanghai, China) for
1 h at room temperature. After incubated with LC3A/B
antibody (#12741, 1:1000, Cell Signaling Technology,
Danvers, USA) overnight at 4 °C, the slides were washed
with PBS and then incubated with Alexa Fluor 647s
antibody (#bs-0295G-AF647, Bioss, Woburn, USA). The
cells were stained with nuclear dye DAPI (#C0080;
Solarbio, Shanghai, China). All the images were captured
with the fluorescence microscope, and representative
images were shown.
Myeloma xenograft tumor mouse model and 5TMM mouse
model
MM cells (1 × 106) of OCI-MY5 and OCI-MY5-
SRD5A1-OE were injected subcutaneously into the right
and left flank of 6–8 weeks’ male/female NOD. Cg-Rag1
(NSG) mice (Vital River Laboratory, Beijing, China) (n=
8), respectively. The tumor volume was measured with a
caliper every 3 days to evaluate the tumor growth rate.
Once tumors reached 15mm in diameter, mice were
sacrificed by CO2 asphyxiation.
The 5TMM3VT murine myeloma cells (1 × 106) were
injected intravenously into the abdomen of 6-week-old
male/female C57BL/KaLwrij mice (Jackson Laboratory,
Bar Harbor, ME) (n= 14). After 3 days, SRD5A1 inhibitor
Dutasteride treatment used on seven mice and intraper-
itoneally injected at the dose of 25 mg/kg three times a
week until all the mice were dead. The time of death
caused by paralysis in the control group and the
Dutasteride group was recorded in turn. All animal work
was performed in accordance with the Guide for the Care
and Use of Laboratory Animals (National Institutes of
Health, USA) and approved by the Animal Ethical and
Experimental Committee of Nanjing University of Chi-
nese Medicine (ACU-15 & ACU170501).
For additional detailed methods, please refer to the
Supplementary Materials and Methods.
Statistical analysis
All data were shown as means ± SEM and performed
using the GraphPad Prism program. Multiple groups were
analyzed by one-way ANOVA, and paired groups were
analyzed by Student’s t test, the survival data were plotted
using Kaplan–Meier curve and analyzed by log-rank
(Mantel–Cox) test. P < 0.05 was considered as significant.
Results
Increased SRD5A1 expression is correlated with poor
survival in MM patients
To understand the clinical outcome of SRD5A1
expression, we examined the data about multiple cancers
from the Cancer Genome Atlas (TCGA) using GEPIA
online tool with customizable functional analysis, such as
tumor/normal differential gene profiling and patient
survival analysis9. The Kaplan–Meier analysis demon-
strated that high SRD5A1 level was associated with poor
prognosis for multiple cancer patients, such as glio-
blastoma multiforme, acute myeloid leukemia, mesothe-
lioma, pancreatic adenocarcinoma, etc. (Fig. 1A–D and
Supplementary Fig. S1A–C), and SRD5A1 was almost
exclusively upregulated in tumor tissues relative to nor-
mal counterparts (Supplementary Fig. S1D, E). Moreover,
we further explored the detailed expression of SRD5A1 in
plasma cells of MM patients during different disease
stages using datasets from NIH Gene Expression Omni-
bus (GSE2658). As shown in Fig. 1E, the expression of
SRD5A1 was significantly increased successively from
normal people (NP), monoclonal gammopathy of unde-
termined significance (MGUS) to MM patients. In
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addition, MM patients bearing high SRD5A1 expression
suffered poor prognosis compared to low SRD5A1
expression patients in TT2 (Total Therapy 2) cohort.
Furthermore, high SRD5A1 expression was linked to
shorter response duration of both event-free survival (EFS)
and overall survival (OS) (Fig. 1F, G). As shown in Fig. 1H,
we further tested SRD5A1 mRNA expression in MM
patients from phase III APEX (assessment of proteasome
inhibition for extending remissions) trials which evaluated
the response to standard therapies (bortezomib or dex-
amethasone), supporting that SRD5A1 might be relevant
to myeloma relapse10. Taken together, we proposed that
SRD5A1 might function as an oncogene in MM.
Knockdown of SRD5A1 induces growth suppression, cell
cycle arrest, and apoptosis in MM cells
To determine whether SRD5A1 functions as an onco-
gene in MM, we functionally knocked down SRD5A1 in
myeloma cells by expressing the lentivirus-mediated
SRD5A1-shRNA which was under the control of a
doxycycline (Dox)-inducible gene promoter thus avoiding
the adverse effect of long-term knockdown. Western
blotting verified a remarkable downregulation of SRD5A1
expression in both ARP1 and H929 human MM cells after
Dox treatment compared with nontreated cells (Fig. 2A).
Both ARP1- and H929-SRD5A1-KD cells exhibited a sig-
nificantly lower cell growth rate following 48 h of treat-
ment with Dox (Fig. 2B).
To elucidate the diminished cell viability of SRD5A1-
KD cells, cells were stained with PI to detect cell cycle by
flow cytometry. As shown in Fig. 2C, the knockdown of
SRD5A1 caused abnormal cell cycle arrest. We observed a
similarly remarkable reduction of G2/M-phased cells of
both ARP1 and H929, with a fluctuation of the G0/G1 and
S phases in these two cell lines. In addition, the cell
growth alteration may not be due to the cellular senes-
cence, as few SA-β-gal-positive cells were found (Sup-
plementary Fig. S2). Meanwhile, the decreased growth
rate of SRD5A1-KD cells was ascribed to increased
apoptotic cell death, which was evidenced by increased
Fig. 1 SRD5A1 is a poor prognostic marker in MM. A–D Kaplan–Meier analysis of OS time, revealing that high SRD5A1 expression conferred
inferior outcomes. E Histogram depicted the SRD5A1 signal in NP, MGUS, and newly diagnosed MM patients. F–H Kaplan–Meier analysis was
performed based on SRD5A1 expression in different cohorts, the MM patients with high SRD5A1 expression had a significantly inferior OS and EFS
time, and OS time was also analyzed in the APEX clinical trials. *P < 0.05, **P < 0.01, ***P < 0.001.
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Fig. 2 Inducible downregulation of SRD5A1 influences growth and survival of myeloma cells in vitro. A Western blotting analysis for SRD5A1
expression of ARP1- and H929-SRD5A1-KD cells treated with or without Dox. B Histogram plot depicted the growth of ARP1- and H929-SRD5A1-KD
cells treated with or without Dox. C PI-staining cell cycle analysis of ARP1- and H929-SRD5A1-KD cells treated with or without Dox. D Western
blotting revealed that SRD5A1 knockdown-induced apoptosis by detecting the expression of PARP and cleaved caspase-3 proteins. E Immunoblot
analysis of Bcl-xl, Bcl-2, Bad, and Bax protein levels in ARP1- and H929-SRD5A1-KD cells treated with or without Dox. F Annexin-V/PI staining indicated
that more apoptosis cells were induced post downregulation of SRD5A1 in ARP1 and H929 cells. G Quantification of apoptosis cells rate in (F).
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expression of cleavage of Poly ADP-ribose polymerase
(PARP) and cleaved caspases-3 (Fig. 2D). We subse-
quently confirmed that knockdown of SRDA51 decreased
the expression of Bcl-2 and Bcl-xl and increased the level
of Bad and Bax (Fig. 2E). Consistently, the Annexin-V/PI
staining assay by flow cytometry determined that more
than threefold apoptotic cells were induced post by sup-
pression of SRD5A1 (Fig. 2F, G). Therefore, transient
knockdown of SRD5A1 could induce cell growth arrest
and apoptosis in MM cells.
Overexpression of SRD5A1 accelerates MM cell growth
To further evaluate the impact of SRD5A1 on cell
growth in vivo, we overexpressed SRD5A1 by lentivirus-
mediated SRD5A1-cDNA transfection in the MM cell
lines ARP1 and OCI-MY5. After assessing overexpression
efficiency (Fig. 3A, B), we injected OCI-MY5 and OCI-
MY5-SRD5A1-OE subcutaneously into the right and left
flank of NSG mice. As shown in Fig. 3C–F, after about
30 days, the tumors derived from OCI-MY5-SRD5A1-OE
cells were visibly bigger than their OCI-MY5 counter-
parts. The average weight of OCI-MY5-SRD5A1-OE
tumors was lower than the control tumors. These
results indicate that genetic overexpression of SRD5A1
facilitates myeloma in vivo, confirming the oncogenic
roles of SRD5A1 in MM cells.
Downregulation of SRD5A1 induces autophagy via
regulating the PI3K/Akt/mTOR pathway in MM cells
To further elucidate the mechanism, we prepared RNA
samples for transcriptomic RNA sequencing (RNA-seq)
to screen differentially expressed genes (DEGs) following
the SRD5A1 knockdown. As shown in Fig. 4A–C, in a
comparison between ARP1-SRD5A1-KD cells treated
with or without Dox, the transcriptome analysis found
145 downregulated genes and 507 upregulated genes. The
KEGG pathway enrichment of these DEGs hinted that
SRD5A1 knockdown may significantly regulate many
pathways, such as autophagy animals, apoptosis, mTOR
signaling pathway, PI3K-Akt signaling pathway among the
top 50 enriched pathways (with the top 20 enriched
pathways shown in Fig. 4B). In addition, by querying
Human Autophagy Database (http://www.autophagy.lu/
index.html) with these above DEGs, we noticed that 21 (4
downregulated and 17 upregulated) could also be directly
annotated as autophagy genes, indicating that SRD5A1
knockdown may be related to autophagic progress (Fig.
4C). Supporting this, we further examined gene expres-
sion profiling (GEP) of 22 normal people and 351 MM
patients from the total therapy 2 (TT2) dataset, finding
more autophagy genes with high expression than that of
the low expression from the TT2 dataset (Supplementary
Fig. S3A, B). Thus, we proposed that autophagy might be
a target pathway influenced by SRD5A1 knockdown.
To verify these findings, scanning electron microscopy
was firstly utilized to evaluate autophagosomes and autop-
hagolysosomes, finding that the number of them was only
slightly increased in SRD5A1-KD myeloma cells compared
to control (Fig. 5A, B). Next, western blotting confirmed the
increased expression of several autophagy marker proteins
including SQSTM1/p62, ATG-5, ATG-7 protein as well as
LC3 conversion after SRD5A1 knockdown (Fig. 5C). In
addition, the expression of LC3 proteins was also confirmed
using immunofluorescence staining methods. As shown in
Fig. 5D, LC3 reached peak expression after Dox treatment
for 24 h in SRD5A1-KDMM cells. Therefore, we concluded
that SRD5A1 knockdown-induced autophagy in MM cells.
The aforementioned KEGG pathway analysis suggested
that SRD5A1 knockdown influenced the PI3K/Akt and
mTOR signaling pathways. To test whether SRD5A1-KD
induced autophagy via the PI3K/Akt/mTOR pathway, we
first detected marker proteins in potential autophagy-
related pathways, such as Ras and PTEN, but there was no
apparent variation (Fig. 5E). However, another autophagy-
related pathway was examined and shown in Fig. 5F that
the phosphorylated protein levels of p-PI3K, p-Akt, p-
mTOR, p-FoxO1, and p-p70S6K were obviously down-
regulated, whereas the protein level of Akt, mTOR, and
p70S6K was elevated slightly or maintained unchanged in
these cells following SRD5A1 knockdown. It indicated
that knockdown of SRD5A1 may induce autophagy
through regulating the PI3K/Akt/mTOR pathway.
SRD5A1 knockdown-induced apoptosis could be
aggravated by autophagy inhibitor 3-methyladenine in
MM cells
Autophagy and apoptosis are two essential self-
destructive processes that regulate cell survival and
death, and their relationship is complex because autop-
hagy constitutes an adaptive response to diverse stress
stimuli for avoiding cell death; yet, in some settings, it can
also contribute to the demise of cells11. To test this, we
first compared the impact of three different autophagy
inhibitors, LY294002, hydroxychloroquine (HCQ), and 3-
methyladenine (3-MA) on MM cell viability in a dosage
range of 0.1–105 nM. Results showed that 3-MA pre-
sented less inhibitory effect on cell viability compared to
HCQ and LY294002 (Supplementary Fig. S4). Hence, we
chose 3-MA to process SRD5A1-KD cells separately or
with Dox jointly for different exposure times. Compared
to the Dox group or 3-MA group for short treatment time
(Dox 24 h and 3-MA 12 h), the MTT assay illustrated that
the inhibitory effect of combined Dox and 3-MA was the
most obvious at 24-h treatment with 3-MA meanwhile
48-h Dox induced SRD5A1 suppression (Fig. 6A).
Based on the results above, we proposed that 3-MA
exerted its inhibitory effect on autophagy thus may
potentiate apoptosis. The results of western blotting
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reinforced (Fig. 5B) expression of cleaved caspase-3 and
cleaved PARP having a significant increase after treated with
3-MA for 24 h in SRD5A1-KD cells (Fig. 6B). Given all that,
these results support the point that SRD5A1 knockdown-
induced apoptosis could be aggravated by 3-MA mediated
autophagy inhibition in MM cells, which could be applied as
a novel therapeutic notion for cancer treatment.
SRD5A1 inhibitor, Dutasteride, possesses a therapeutic
effect on MM
To further explore the therapeutic utilization of the pre-
sent preclinical study, we evaluated the effect of the SRD5A1
inhibitor Dutasteride on MM cell growth. As shown in
Fig. 7A, Dutasteride dramatically reduced the viability of
ARP1 and H929 cells, with IC50 at 78.446 μM and
17.156 μM, respectively. The western blotting results
demonstrated that Dutasteride suppressed SRD5A1 expres-
sion in MM cells post treatment with two dosages (20 μM,
50 μM) for 48 h and 72 h. Meanwhile, we observed the
increased expression levels of cleaved caspase-3 and cleaved
PARP in a time- and dose-dependent manner (Fig. 7B).
Consistent with the previous results in SRD5A1-KD cells
(Fig. 5), the PI3K/Akt/mTOR signaling pathway was sup-
pressed after Dutasteride treatment (Fig. 7C).
In order to further explore the antitumor effect of
SRD5A1 inhibition, Dutasteride was intraperitoneally
injected to MM mice (25 mg/kg body weight, three times/
week) once the 5TMM3VT syngeneic MM-prone-model
was established. Time-course analysis of tumor growth
revealed that control MM mice rapidly deteriorated from
day 22 until all mice were dead by day 32. However,
Dutasteride-treated MM-prone mice exhibited prolonged
survival rates up to 50 days (P= 0.0060; Fig. 7D).
Therefore, downregulation of SRD5A1 outstandingly
lagged the myeloma tumor growth in vivo.
Discussion
Differing from necrosis, apoptosis is a highly programmed
cell death process and is typically dysregulated in human
cancers12. Massive apoptosis can induce the death of cancer
Fig. 3 SRD5A1 overexpression promotes MM cellular proliferation in vitro and in vivo. A Western blotting analysis for SRD5A1 expression of
WT and SRD5A1-OE cells. B Histogram plot depicted the growth of WT and OCI-MY5 SRD5A1-OE cells. C The oncogenic effect of SRD5A1 was
examined in subcutaneous transplantation mouse models using OCI-MY5 WT and OCI-MY5 SRD5A1-OE cell lines. The result indicated that
SRD5A1 significantly promoted OCI-MY5 tumor growth. D After treatment, the tumor weight of the SRD5A1-OE group was higher than that of the
WT group. E, F The NOD-SCID mice injected subcutaneously with OCI-MY5 WT (left) and OCI-MY5 SRD5A1-OE (right) cells were sacrificed, and tumors
were isolated. *P < 0.05, **P < 0.01, ***P < 0.001.
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cells, while aberrant apoptosis contributes to cancer initia-
tion, progression, and treatment failure13. The specific
molecular mechanism was uncovered in the 1990s, parti-
cularly specific genes regulating cell death in Caenorhabditis
elegans and the B-cell lymphoma 2 (Bcl-2) was discovered as
an arbitrator in apoptosis14. The Bcl-2 family controls
apoptosis-mediated mitochondrial outer membrane per-
meabilization (MOMP) and includes the anti-apoptotic
proteins (Bcl-2, Bcl-xL, and Mcl-1), pro-apoptotic effectors
(Bak and Bax), and pro-apoptotic BH3-only proteins (Bid,
Bim, Bik, Noxa, and Puma)15,16. The executor of apoptosis
caspase activation results in MOMP, thereby releases
apoptotic components, such as cytochrome c, Smac, and
Omi. Nowadays targeting apoptosis has been increasingly
recognized as a promising approach to kill cancer cells17.
Our results detecting changed Bcl-2 family proteins in
Figs. 2 and 7 strongly support that inhibition of SRD5A1 by
either RNAi or drugs (Dutasteride) treatment facilitates
apoptosis instead of necrosis or cellular senescence in MM
cells. Although Bcl-2 family proteins are initially regarded as
regulators of cell death, they also participate in autophagy by
constitutively interacting with Beclin-1, which promotes
autophagy and inhibits tumorigenesis in mammalian
cell18,19.
The term “autophagy” was coined by Christian de Duve
at the Ciba Foundation Symposium on Lysosomes for the
Fig. 4 RNA sequencing results reveal differentially expressed genes (DEGs) and enriched KEGG pathways in MM cells after downregulating
SRD5A1. A Transcriptiomic RNA-seq identified 652 DEGs. Hierarchical cluster analysis (top) of significantly differentially expressed mRNAs between
ARP1-SRD5A1-KD cells treated with and without Dox. Volcano plot (bottom) showing 145 decreased genes and 507 upregulated genes. B Top
enriched KEGG pathways for these 652 DEGs, including autophagy and apoptosis signaling. C Twenty-one DEGs (including four downregulated and
17 upregulated genes) could be annotated as the autophagy-related genes from Human Autophagy Database.
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first time in groundbreaking work on the discovery of
lysosomes in the 1950s, but massive researches began in
2008 (refs. 20,21). Recent reports indicate that autophagy
plays a dichotomous role in tumorigenesis: extravagant
autophagy triggers cancer cells to “autophagic cell death”
(ACD) through excessive self-digestion and degradation
of essential cellular constituents22, while more often,
under normal physiological conditions, autophagy func-
tions as a patron to counteract with cancer by eliminating
damaged organelles and recycling degradation products23.
Fig. 5 SRD5A1 knockdown induces autophagy via PI3K/Akt/mTOR pathway. A The ultrastructure of autophagosome in ARP1- and H929-
SRD5A1-KD treated with Dox compared to SRD5A1-KD cells observed by transmission electron microscopy. B The level of autophagosome in (A) was
quantified. One-way analysis of variance (ANOVA) was carried out. C Western blotting assay on SQSTM1, ATG-7, ATG-5, and LC3 expression in ARP1-
and H929-SRD5A1-KD cells treated with or without Dox. D Immunofluorescence staining of LC3 expression in ARP1- and H929-SRD5A1-KD cells
treated with or without Dox. E Western blotting assay on PTEN and Ras expression in ARP1- and H929-SRD5A1-KD cells treated with or without Dox.
F Expression of a marker protein in PI3K/Akt/mTOR signaling was detected by western blotting in ARP1 and H929 cells.
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Autophagy is observed at a higher frequency in cancer
cells than in normal cells, and some cancers even count
on autophagy for survival under external stresses such as
starvation, hypoxia, growth factor withdrawal, che-
motherapy, or radiotherapy24,25. In this study, SRD5A1
knockdown-induced autophagy existed merely in the
beginning phase after treatment of Dox (before 24 h) and
vanished at 48 h according to our observation (Figs. 5D
and 6A). Hence, we suspected autophagy might be an
attempt of MM cells for survival, so we went on to verify
that inhibiting autophagy by 3-MA could contribute to
cell death (Fig. 6B).
However, the cross-talk between apoptosis and autop-
hagy is complex and still vague, as synergistic,
Fig. 6 3-MA potentiates apoptosis induced by inhibition of autophagy. A Effect of 3-MA and/or Dox on the growth of ARP1 and H929-SRD5A1-
KD cells measured by MTT assay. B Western blotting analysis of SQSTM1, caspase-3, cleaved caspase-3 and PARP, cleaved PARP in response to 3-MA
and/or Dox treatment in ARP1- and H929-SRD5A1-KD cells. *P < 0.05, **P < 0.01, ***P < 0.001.
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Fig. 7 Dutasteride possesses a therapeutic effect on MM. A MTT proliferation assay of ARP1 and H929 cells treated with different concentrations
of dutasteride for 48 or 72 h. B Expression of apoptosis markers in dutasteride-treated ARP1 and H929 cells as determined by western blotting
analysis. C Western blotting showed that Dutasteride treatment inhibited the activity of PI3K/Akt/mTOR signaling in ARP1 and H929 cells. D An MM
model was established by injecting 8-week-old C57BL/KaLwRij mice with intravenous 5TMM3VT via the tail vein (1 × 106 cells per mouse; n= 7 per
group). The survival curves of the 5TMM3VT mouse model with or without Dutasteride treatment are presented. E The model of our working
hypothesis. Reduced SRD5A1 expression triggers apoptosis and autophagy activation eventually leads to cell death when autophagy cannot
compensate for apoptosis-induced cellular stress.
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antagonistic, and interdependent effects have been
observed26. Normally, autophagy precedes apoptosis and
maintains homeostasis, as reflected by that inhibition of
autophagy leads to accumulation of damaged and harmful
cellular constituents, which in general increases cellular
stress levels and activates sensitivity against programmed
cell death22. Programmed cell death, such as apoptosis, is
triggered once cellular stress is prolonged for a critical
duration or exceeds the intensity threshold. Several stu-
dies have reported that these two highly conserved pro-
cesses are tightly regulated by overlapping components
and can interact with each other in many types of cancers,
such as Beclin-1/Bcl-2 and FLIP (FADD-like IL-1b-
converting enzyme-inhibitory protein), autophagy-
related proteins (ATGs), caspases27. Targeting apoptosis
has been the overwhelming focus of methods aimed at
killing cancer cells, and experimental evidence shows that
autophagy participates in resistance to chemotherapy-
induced cell death28. In MM cells, the abnormal autop-
hagy could regulate proliferation and apoptosis, which
advances the progress of MM29,30. In this study,
SRD5A1 suppression simultaneously induced apoptosis
through Bcl-2 family proteins as well as autophagy via
PI3K/Akt/mTOR signaling, meanwhile, the autophagy
inhibition using 3-MA potentiated MM cell apoptosis.
Consistent with our findings, one recent study report that
silencing of the stress-related nuclear protein 1 (NUPR1)
could suppress autophagy activities and induces
autophagy-mediated apoptosis in two MM cell lines
(U266 and RPMI 8226) through the PI3K/AKT/mTOR
pathway31. In fact, the autophagy inhibitor drug chlor-
oquine could also potentiate carfilzomib-induced apop-
tosis in myeloma cells in vitro and in vivo32. Therefore,
the above findings support the therapeutic utilization of
trials targeting both autophagy and autophagy-mediated
apoptosis to improve anti-MM therapy33.
To the best of our knowledge, this study for the first time
established a link between the dual-autophagy–apoptosis-
regulatory SRD5A1 and the activity of MM. SRD5A1, which
maps to a previously defined amplicon at 5p15.31, catalyzes
the conversion of testosterone into the more potent
androgen, dihydrotestosterone (DHT), which was sig-
nificantly overexpressed in newly diagnosed MM patients
with a short survival34,35. Elevated levels of SRD5A1 have
been reported to be correlated to the severity of multiple
cancers with their nidus situated to the parts rich in sex
hormone, including prostate cancer, breast cancer, endo-
metrial cancer, or the like, and to facilitate cell prolifera-
tion32. Nonetheless, neither testosterone nor DHT has an
impact on myeloma cell proliferation in this study (data not
shown), but we did find that varying levels of SRD5A1 could
alter the growth of myeloma cells. It may be mainly due to
the oncogenic role of SRD5A1 in these tumor cells including
MM and other prostate cancers (Fig. 1). However, we
cannot exclude the indirect roles of its enzymatic
substrate–androgens in the MM pathogenesis. Although a
recent study indicated that SRD5A1−/− mice had reduced
bone mass and diminished areal bone mineral density
without changed circulating levels of androgens in serum, it
may be explained by the compensatory adjustment of ster-
oids metabolism among SRD5A1, SRD5A2, SRD5A3
(ref. 36). In fact, it is evidenced that tumor development is
relevant to the metabolism of steroids within the local tumor
and its adjacent host tissue which might create a micro-
environment to promote the cancer37. Besides, the effects of
testosterone can also be exerted through aromatization to
estrogens, which could exert their carcinogenic effects
through binding with estrogen receptors38. There are two
5α-reductase inhibitors tested clinically with Finasteride
specifically inhibiting SRD5A2 and Dutasteride targeting
both SRD5A1 and SRD5A239,40. We also presented the
therapeutic effect of SRD5A1 inhibitor Dutasteride on MM
(Fig. 6). Further preclinical studies are needed to evaluate the
detailed mechanism as well as its therapeutic potential
in vivo. Therefore, the results presented herein characterize
a novel mechanism by which SRD5A1 can be a novel target
in MM, and it is urgent to develop more novel agents spe-
cifically targeting SRD5A1.
Taken together, we discovered the previously unclear
role of SRD5A1 in MM. SRD5A1 simultaneously reg-
ulates both apoptosis mediated by Bcl-2 proteins family
and autophagic process via PI3K/Akt/mTOR signaling
(Fig. 7E). On the basis of this dual autophagy–apoptosis
regulatory potential of SRD5A1, we propose that SRD5A1
may be a potential novel target for MM.
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